238 studies found for:    HSA
Show Display Options
Rank Status Study
1 Recruiting Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Non-Resectable Cholangiocarcinoma;   Pancreatic Adenocarcinoma;   Recurrent Gallbladder Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Gallbladder Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Unresectable Gallbladder Carcinoma;   Unresectable Pancreatic Cancer
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Biological: Recombinant EphB4-HSA Fusion Protein
2 Not yet recruiting Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs
Condition: Stage IV Bladder Urothelial Carcinoma
Interventions: Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Procedure: Positron Emission Tomography;   Biological: Recombinant EphB4-HSA Fusion Protein
3 Completed Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: succinylated human serum albumin
4 Recruiting Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis;   Other: pharmacological study;   Biological: recombinant albumin fusion protein sEphB4-HSA
5 Unknown  Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests
Condition: Allergic Rhinitis
Interventions: Drug: saline with 1mg/ml Histamine base;   Drug: diluent, saline with HSA--phenol
6 Completed Phase I BP Interferon (IFN) Beta-004
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Interferon beta-1a HSA-free biosimilar;   Drug: Interferon beta-1a HSA+ biosimilar;   Drug: Interferon beta-1a original
7 Completed
Has Results
Voluven® in Paediatric Patients
Conditions: Cardiac Surgery;   Cardiopulmonary Bypass
Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L);   Drug: Human serum albumin (HSA 50g/L)
8 Terminated
Has Results
Treatment of Subarachnoid Hemorrhage With Human Albumin
Condition: Subarachnoid Hemorrhage
Intervention: Drug: 25% human albumin
9 Recruiting Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein
Condition: Chemotherapy-induced Neutropenia
Interventions: Drug: HSA-GCSF 1.2 mg;   Drug: HSA-GCSF 1.5 mg;   Drug: GCSF
10 Completed in Vitro Fertilization (IVF) Media Protein and Live Birth Rates
Conditions: Infertility;   Pregnancy Outcome, Live Birth;   In Vitro Fertilization
Interventions: Other: 10% SSS embryo culture medium protein supplementation;   Other: 0.5% HSA embryo culture medium protein supplementation
11 Terminated Study to Evaluate the Safety of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients
Condition: Hypovolemia
Intervention: Drug: Kedbumin 25%
12 Unknown  A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA
Conditions: Healthy;   SIRS
Intervention: Other: 123 I-HSA + 125 I HSA
13 Completed Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Biological: Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.;   Biological: Peginterferon 180 mcg single dose S.C.
14 Completed Efficacy and Safety of Plasma Exchange With 5% Albutein in Beta-Amyloid Peptide Clearance in Cerebrospinal Fluid
Condition: Alzheimer's Disease
Intervention: Biological: Albutein 5%
15 Terminated Treatment of Subarachnoid Hemorrhage With Human Albumin
Condition: Subarachnoid Hemorrhage
Intervention: Drug: Human Albumin
16 Completed VolulyteTM in Cardiac Surgery
Condition: Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions: Drug: 6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM);   Drug: Human serum albumin
17 Not yet recruiting Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients
Condition: Hemodynamic Stability
Interventions: Drug: Lactated Ringer's;   Drug: 5% Human Albumin
18 Completed Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients
Condition: Chronic Hepatitis B
Interventions: Biological: Human Serum ALbumin/interferon alpha2a;   Biological: Pegasys
19 Active, not recruiting Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI
Condition: Acute Myocardial Infarction
Interventions: Other: Allogeneic human cardiac stem cells (CSCs);   Other: Human Serum Albumin-HSA 5%
20 Enrolling by invitation The Effect of Human Albumin on Coagulation Competence and Hemorrhage
Condition: Hemorrhage; Complicating Delivery, Coagulation Defect
Interventions: Drug: 5% Human Albumin " Behring";   Drug: Lactated Ringer

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years